




PHARMACEUTICAL 2019

Q BioMed Inc.
Rank 331 of 363





PHARMACEUTICAL 2019

Q BioMed Inc.
Rank 331 of 363

The relative strengths and weaknesses of Q BioMed Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Q BioMed Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 18% points. The greatest weakness of Q BioMed Inc. is the variable Net Income, reducing the Economic Capital Ratio by 170% points.

The company's Economic Capital Ratio, given in the ranking table, is -283%, being 320% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	2,697
Cost of Goods Sold	0
Intangible Assets	500
Liabilities, Current	429
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	2,873
Other Net Income	0
Other Revenues	0
Property and Equipment	0
Research and Development	3,238
Selling, General and Administrative Expense	5,782

Output Variable	Value in 1000 USD
Assets	3,197
Liabilities	3,303
Expenses	9,020
Revenues	0
Stockholders Equity	-106
Net Income	-9,020
Comprehensive Net Income	-9,020
Economic Capital Ratio	-283%